Nuo Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Nuo Therapeutics Inc (NUOT) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Nuo Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 4M vs 66,556M combined for its competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+29.1% annualized vs trailing 12 months), vs decelerating (-7.9%) for its tracked peer group.
- Growth: Nuo Therapeutics Inc generated 168.8% revenue growth year over year in Q1 2026, vs 3.4% for its competitors combined.
- Profitability: Its -47.5% net margin compares with 15.3% for the peer group.
- Peer revenue share: Nuo Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $0.40M compares with $0.74M for the peer group (0.5x).
- Structure: Nuo Therapeutics Inc operates in the following segments: Single Reportable Segment.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
NUOT Sales vs. its Competitors, Q1 2026
Nuo Therapeutics Inc reported revenue growth of 168.82 % year on year in Q1 2026, above its competitors' combined revenue growth of 3.44 %.
With a net margin of -47.50 %, Nuo Therapeutics Inc reported lower profitability than its competitors (15.29 %).
Nuo Therapeutics Inc generated 0.01 % of the combined sales of its peer group, up from 0.00 % a year earlier.
API endpoints for this dataset
Nuo Therapeutics Inc vs. its Competitors, Q1 2026
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in Nuo Therapeutics Inc reports; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Nuo Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Nuo Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (3) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Nuo Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Medical Equipment & Supplies industry grew revenue 14.4% year over year, combined, vs 168.8% for Nuo Therapeutics Inc. Nuo Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Nuo Therapeutics Inc's Competitor Quality Breadth
Group definitions: see Methodology: Performance Group Definitions.
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Nuo Therapeutics Inc | No | Yes | Yes | No |
| Competitors combined (23) | ||||
| High-Confidence Competitors (4) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
NUOT Stock Performance relative to its Competitors
NUOT Stock Performance relative to High-Confidence Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Avita Medical Inc | 282.9% | Outperformed |
| 2 | Pulse Biosciences Inc | 282.9% | Outperformed |
| 3 | Pro dex Inc | 282.9% | Outperformed |
| 4 | Anika Therapeutics Inc | 282.9% | Outperformed |
| 5 | Amgen Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Nuo Therapeutics Inc's best-performing competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Nuo Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Nuo Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
 Nuo Therapeutics Inc |
- | 4.04 |
 Amgen Inc |
253,085.12 | 38,095.00 |
 3m Company |
98,578.04 | 25,247.00 |
 Smith and Nephew Plc |
13,553.33 | 6,164.00 |
 Pulse Biosciences Inc |
4,025.37 | 1.19 |
 Establishment Labs Holdings Inc |
2,063.94 | 245.11 |
| SUBTOTAL | 375,393.00 | 73,167.57 |
Sign in to see all competitors of Nuo Therapeutics Inc .
Sources: see Methodology: Peer & Competitor Identification, Sourcing.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Nuo Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Nuo Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from Nuo Therapeutics Inc reports and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Smith and Nephew | Company report | 85% |
| MiMedx | Company report | 85% |
| ConvaTec | Company report | 85% |
| MoInlycke | Company report | 85% |
| Integra Life Sciences | Company report | 85% |
| Smith+Nephew | Company report | 85% |
| Organogenesis | Company report | 85% |
| 3m Company | Company report | 85% |
| Avita Medical Inc | Company report | 85% |
Company report basis, confidence, active dates and source counts for Nuo Therapeutics Inc's named competitors require a Commercial License.
Methodology: see Methodology: Peer & Competitor Identification, Sourcing.
Nuo Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Nuo Therapeutics Inc | Single Reportable Segment 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| 3m Company | Safety and Industrial 48.33 % |
| Pulse Biosciences Inc | Single Reportable Segment 100.00 % |
| Integra Lifesciences Holdings Corp | Specialty Surgery 73.96 % |
| Anika Therapeutics Inc | Single Reportable Segment 100.00 % |
Source: operating segment revenue as reported in each company's reports (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Nuo Therapeutics Inc .
Nuo Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Nuo Therapeutics Inc | - | 403,569 | -238,455 |
| Amgen Inc | 253,085 | 2,930,385 | 672,538 |
| 3m Company | 98,578 | 417,306 | 58,579 |
| Smith and Nephew Plc | 13,553 | 362,844 | 36,791 |
| Pulse Biosciences Inc | 4,025 | 10,216 | -690,138 |
| Establishment Labs Holdings Inc | 2,064 | 244,128 | -38,736 |
| PEERS TOTAL | 375,393 | 736,578 | 126,216 |
Sign in to see all peers for Nuo Therapeutics Inc .
Nuo Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent report. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| 3m Company | United States 46.28 % |
| Establishment Labs Holdings Inc | Non-US 63.84 % |
| Integra Lifesciences Holdings Corp | United States 72.80 % |
| Inmode Ltd | US 53.62 % |
| Avita Medical Inc | US 96.46 % |
Source: revenue geography as reported in each company's reports (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Nuo Therapeutics Inc .
Nuo Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Medical Equipment & Supplies industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Medical Equipment & Supplies industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 67.01 % | 46.20 % (avg) | +20.8 pp |
| Operating Margin | -54.96 % | industry median | -45.5 pp |
| EBITDA Margin | -61.08 % | -6.66 % (avg) | -54.4 pp |
| Capital Intensity (Capex / Revenue) | 1.13 % | 7.13 % (avg) | -6.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Nuo Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in company reports.| Metric | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 0.00 % | -96.86 % | 279.31 % | -100.00 % | - | - | 124.34 % | 135.72 % |
| Operating Margin | -358.96 % | -1,548.58 % | -109.78 % | - | - | - | - | -78.21 % |
| Return on Invested Capital | -333.14 % | -41.77 % | - | - | -67.27 % | -159.49 % | -190.39 % | - |
| P/E | - | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Nuo Therapeutics Inc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 1.13 % vs industry average 7.13 % (see Profitability & Cost Structure above) |
Note: see Methodology: Porter's Five Forces. Supplier power and buyer power are covered on Nuo Therapeutics Inc's dedicated Suppliers and Customers pages, not here.
Nuo Therapeutics Inc's Industry Attractiveness & Competitive Strength
See Methodology: GE/McKinsey Matrix for how the two axes are built.
Nuo Therapeutics Inc falls in the Low attractiveness / Low strength cell: Harvest / Divest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Nuo Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Latest-quarter revenue run-rate is accelerating (+29.1% annualized vs trailing 12 months).
Weaknesses
- Operating margin 45.5 points below the industry median.
Opportunities
- A meaningful share of competitors (34.80 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-7.9% annualized).
Methodology: see Methodology: SWOT Analysis.
Nuo Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Nuo Therapeutics Inc | 0.33 | 1.06 | - |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| 3m Company | - | 1.47 | 3.62 |
| Smith and Nephew Plc | 0.35 | 2.57 | - |
| Pulse Biosciences Inc | 9.01 | 9.31 | - |
| Establishment Labs Holdings Inc | 0.95 | 3.26 | 13.16 |
Sign in to see all peers for Nuo Therapeutics Inc .
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Nuo Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Nuo Therapeutics Inc | Q1 2026 | +168.8 % | - |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| 3m Company | Q3 2026 | +1.0 % | +63.3 % |
| Smith and Nephew Plc | Q4 2025 | +6.1 % | +51.7 % |
| Pulse Biosciences Inc | Q2 2026 | - | - |
| Establishment Labs Holdings Inc | Q2 2026 | +31.7 % | - |
| PEERS TOTAL | +5.3 % | +55.3 % |
Sign in to see all peers for Nuo Therapeutics Inc .
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Nuo Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Nuo Therapeutics Inc | Q1 2026 | +273.8 % | -99.6 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| 3m Company | Q3 2026 | +0.2 % | +17.4 % |
| Smith and Nephew Plc | Q4 2025 | +6.2 % | - |
| Pulse Biosciences Inc | Q2 2026 | - | -26.8 % |
| Establishment Labs Holdings Inc | Q2 2026 | +23.9 % | +76.2 % |
Sign in to see all peers for Nuo Therapeutics Inc .
Nuo Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Nuo Therapeutics Inc | - | - | - |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| 3m Company | 9.60% | 13.24% | 93.07% |
| Smith and Nephew Plc | 5.98% | 5.98% | 11.82% |
| Pulse Biosciences Inc | - | - | - |
| Establishment Labs Holdings Inc | - | - | - |
Sign in to see all peers for Nuo Therapeutics Inc .
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Nuo Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Nuo Therapeutics Inc | - | - |
| Amgen Inc | 28.90 | 6.64 |
| 3m Company | 28.11 | 3.90 |
| Smith and Nephew Plc | 43.37 | 2.20 |
| Pulse Biosciences Inc | - | 3,396.93 |
| Establishment Labs Holdings Inc | - | 8.42 |
| PEERS AVERAGE | 29.95 | 5.13 |
Sign in to see all peers for Nuo Therapeutics Inc .
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.